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Abstract
Purpose Obstructive sleep apnea (OSA) is characterized by chronic intermittent hypoxia which induces inflammation in 
blood vessels leading to the development of cardiovascular comorbidities. Several studies implicated the role of P-selectin in 
vascular inflammation of OSA. P-selectin glycoprotein ligand 1 (PSGL-1) is the main activator for P-selectin and is involved 
in immune cell trafficking. However, PSGL-1 has not been analyzed in OSA. The aim of the study was to investigate plasma 
PSGL-1 and P-selectin levels to have a deeper understanding on their interaction in obstructive sleep apnea.
Methods Fifty-one untreated patients with OSA and 42 non-OSA controls were recruited. Plasma PSGL-1 levels were 
determined in evening and morning samples, P-selectin levels were analyzed in morning samples using commercially avail-
able ELISA kits. Polysomnography was performed in all participants. OSA was defined by an apnea–hypopnea index ≥ 5/h.
Results PSGL-1 levels did not differ between controls and OSA patients either in the evening or in the morning. Although, 
there was no difference between controls (16.9/6.8–40.8 ng/ml) and patients with OSA (19.6/8.4–56.8, p = 0.24), patients with 
severe OSA had increased plasma P-selectin levels (25.6/8.4–56.8 ng/ml) compared to mild OSA patients (14.1/8.5–35.3 ng/
ml, p = 0.006) and controls (p = 0.03).
Conclusions P-selectin expression relates to disease severity suggesting a pathophysiological role in endothelial cell activa-
tion. PSGL-1 levels are unaltered in OSA, suggesting an alternative activation pathway for P-selectin in OSA.
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Introduction
Obstructive sleep apnea (OSA) is characterized by repetitive 
complete or partial collapse of the upper airways and con-
sequential intermittent hypoxia during sleep. Patients with 
OSA have a higher risk for hypertension, cardiovascular dis-
ease and type-2 diabetes mellitus [1].
Chronic intermittent hypoxia leads to the production of 
pro-inflammatory mediators, such as interleukin 1 β (IL-1β), 
IL-6 and tumor necrosis factor-α [2]. These, together with 
hypoxia itself induce the expression of adhesion molecules, 
such as P-selectin. P-selectin is expressed upon stimulation 
by thrombin [3], hypoxia [4] or cytokines [5] by platelets 
and endothelial cells, however platelet P-selectin expres-
sion may be less important in OSA compared to endothelial 
P-selectin [6, 7]. P-selectin enhances the adhesion between 
leukocytes and endothelial cells thus slowing down the 
rolling of leukocytes and facilitating their extravasation. 
P-selectin has extensively been investigated in OSA [6–12] 
with some studies reporting elevated blood P-selectin levels 
[8, 11, 12], but not all [6, 7, 10]. A potential explanation for 
the contradictory findings could be the presence of comor-
bid obesity, as one study reported no difference in circu-
lating P-selectin levels between OSA and body mass index 
(BMI)-matched controls [6]. In addition, blood P-selectin 
concentrations were related to BMI, but not to the indices 
of disease severity in another study [8], however this has 
been contradicted by a further report [10]. Nevertheless, as 
OSA is frequently associated with obesity [13] which may 
itself induce systemic inflammation [14], potential effect of 
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obesity has to be taken into consideration when interpreting 
the data.
P-selectin glycoprotein ligand 1 (PSGL-1) is expressed 
primarily on the surface of leukocytes [15], but endothe-
lial cells and platelets can also express PSGL-1, albeit in a 
smaller quantity [16]. Its expression in platelets is induced 
by thrombin [17], which levels were reported to be increased 
in OSA [8]. There are no data available if inflammatory 
cytokine cascade seen in OSA can lead to an increased 
expression of PSGL-1 in leukocytes. Rather, it seems that 
inflammation may reconfigure PSGL-1 location on leuko-
cytes to facilitate their binding [18]. In addition, appropriate 
glycosylation of PSGL-1 is essential for P-selectin binding 
and optimal leukocyte rolling [18, 16] and glycosylation 
is increased in active lymphocytes [18]. On the contrary, 
PSGL-1 is downregulated in apoptotic cells [19]. OSA is 
characterized by increased levels of pro-apoptotic [7] and 
decreased concentration of anti-apoptotic [20] molecules. 
The main receptor for PSGL-1 is P-selectin [21]. The main 
function for PSGL-1 is to facilitate leukocyte trafficking 
through endothelial cells. In addition, PSGL-1 has both 
pro-inflammatory role by inducing IL-8 production [22] and 
immunoregulatory effects by supporting regulatory T-cell 
differentiation [16] and inducing the expression of immu-
nosuppressive IL-10 and transforming growth factor-β [23]. 
The levels of both molecules were found to be reduced in 
OSA [24]. Although PSGL-1 is an essential molecule for 
leukocyte differentiation and their trafficking during inflam-
mation, its role in inflammatory diseases is not fully under-
stood [16, 18]. However, PSGL-1 has not been studied in 
OSA yet.
Sleep fragmentation, another hallmark of OSA leads to an 
altered production of circulating hormones and cytokines.[7] 
Investigating evening to morning changes of inflammatory 
biomarkers may explore acute effects of disturbed sleep. In 
addition, this holds important methodological considera-
tions, when to collect samples from OSA patients to study 
inflammatory pathways.
The aim of the study was to analyze the levels of circu-
lating PSGL-1 in OSA. We compared evening to morning 
PSGL-1 concentrations and correlated with markers of OSA 
severity and comorbidities. PSGL-1 levels were investigated 
with its receptor, the P-selectin.
Materials and Methods
Subjects and Design
Ninety-three participants were recruited from those patients 
who were referred to the Sleep Unit of the Department of 
Pulmonology, Semmelweis University due to suspected OSA 
(i.e. snoring, witnessed apneas, daytime somnolence). None 
of the patients had previously been diagnosed with OSA, nor 
had they been treated with continuous positive airway pres-
sure (CPAP) or mandibular advancement devices (MAD). 
Exclusion criteria included any uncontrolled chronic disease, 
history of any malignancy within 10 years, and infection 
within 2 months. Data for screen failures were not captured.
In the evening, after filling out the Epworth Sleepiness 
Scale (ESS) and taking medical history, venous blood was 
taken into EDTA tubes for PSGL-1 measurement. This 
was followed by an attended full-night polysomnography. 
The following morning blood pressure was measured, and 
blood collection was performed in EDTA tubes for plasma 
P-selectin and PSGL-1 as well as in red top tubes for serum 
C-reactive protein (CRP), glucose, total cholesterol, high 
density lipoprotein cholesterol (HDL-C), low density lipo-
protein cholesterol (LDL-C) and triglyceride measurements. 
Blood was sampled at fasting conditions and before taking 
any medication.
The study was approved by the local Ethics Committee 
(Semmelweis University, TUKEB 30/2014) and informed 
consent was obtained from all participating volunteers.
ELISA Measurements
EDTA-treated blood samples were centrifuged within 2 h at 
1500 RPM for 10 min at 4 °C. Immediately following cen-
trifugation, plasma was separated into 250 µL aliquots which 
were stored at − 80 °C until analysis. Samples were thawed 
just before the ELISA measurements. PSGL-1 and P-selectin 
levels were measured using a commercially available ELISA 
kits (Abcam Human PSGL-1 ELISA kit and Sigma-Aldrich 
Human P-selectin ELISA kit) according to the manufactur-
ers’ instructions in duplicates. We reported the mean values 
of the two measurements. We measured PSGL1 levels in 
samples taken in the evening and in the morning, P-selectin 
levels were analyzed in the morning samples. Intra assay 
variability was 6.35% for P-selectin and 25.46% for PSGL-1.
Polysomnography
Polysomnography was performed as it was described previ-
ously [7] using Somnoscreen Plus Tele PSG (Somnomedics 
GMBH Germany). Electroencephalogram, electrooculogram 
and electromyogram, thoracic and abdominal respiratory 
excursions, breath sounds, nasal pressure, electrocardio-
gram and oxygen saturation were recorded. Sleep stages, 
movements and cardiopulmonary events were scored manu-
ally according to the American Academy of Sleep Medicine 
(AASM) guideline [25]. Total sleep time (TST), sleep period 
time (SPT) and minimum oxygen saturation  (MinSatO2) 
were recorded. Apnea–hypopnea index (AHI), respira-
tory disturbance index (RDI), oxygen desaturation index 
(ODI), arousal index (AI) and total sleep time spent with 
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oxygen saturation below 90% (TST90%) were calculated. 
An AHI ≥ 5/h was diagnostic for OSA.
Statistical Analysis
Shapiro-Wilks test was used to test to assess normality 
which showed non-parametric distribution for P-selectin and 
PSGL-1 levels. Mann–Whitney U-test and Chi-square test 
were used to compare clinical and demographic characteris-
tics as well as biomarker levels between the OSA and control 
groups. We applied Kruskal–Wallis test, followed by the 
Dunn’s test to investigate the differences in biomarker levels 
among the OSA severity groups. Plasma biomarker levels 
were correlated with clinical variables using the Spearman’s 
test. All tests were carried out with R v. 3.1.3. Diagrams 
were plotted with the ggplot2 package for R. Kruskal Wallis 
and Dunn’s test were performed with the dunn.test pack-
age for R. A sample size of 93 was estimated to find sig-
nificant differences with an alpha of 0.05, a beta of 0.8 and 
an effect size of > 0.40 with respect to the asymptotic rela-
tive efficiency of non-parametric tests. p values < 0.05 were 




Following polysomnography, 51 patients were diagnosed 
with OSA (44 ± 15 years). Sixteen patients had mild OSA 
(AHI 5–14.9 events/h), 15 had moderate (AHI 15–29.9 
events/h) and 20 had severe (AHI > 30 events/h) disorder. 
Subjects’ characteristics and comparisons between the OSA 
and control groups are summarized in Table 1.
Circulating PSGL‑1 Levels
PSGL-1 levels did not differ between controls and 
OSA patients either in the evening or in the morning 
(494.0/46.9–802.1  U/ml vs. 452.5/254.2–1265.9  U/ml, 
p = 0.67 in the morning, and 480.2/41.3–1027.6 U/ml vs. 
497.5/50.2–1054.7 U/ml, p = 0.70 in the evening in controls 
and OSA patients respectively). Similarly, PSGL-1 levels did 
not change from evening to morning in either group (both 
p > 0.05, Fig. 1.). There was no difference in plasma PSGL-1 
levels among the different OSA severity groups at either time 
point (Table 2). However, there was a significant correlation 
between the evening and morning PSGL-1 levels (ρ = 0.27, 
p = 0.02). There was a trend toward higher PSGL-1 levels in 
obese OSA patients in the morning (530.7/291.1–1130.8 U/
ml vs. 413.4/254.2–1265.2 U/ml, p = 0.06) compared to non-
obese OSA.
Circulating P‑selectin levels
There was no difference between OSA patients and controls 
in P-selectin levels (p > 0.05). However, circulating P-selec-
tin levels were significantly different among the OSA sever-
ity groups (Kruskal–Wallis test, p = 0.01, Table 2). After 
post-hoc testing we found that patients with severe OSA had 
increased plasma P-selectin levels compared to mild OSA 
patients (p = 0.006) and controls (p = 0.03, Fig. 2).
Circulating P‑Selectin Levels and Comorbidities
There was a trend for elevated P-selectin levels in hyper-
tensive patients with OSA (N = 37, 22.9/8.4–56.8  ng/
ml) compared to patients without hypertension (N = 14, 
13.7/10.6–35.3  ng/ml, p = 0.057). There was no differ-
ence between controls with (N = 13, 14.5/6.8–40.8  ng/
ml) and without (N = 29, 18.6/12.6–24.6 ng/ml, p = 0.31) 
hypertension.
P-selectin was significantly higher in obese OSA patients 
(BMI ≥ 30 kg/m2, N = 26, 29.9/8.4–56.8/ng/ml) compared to 
non-obese patients (N = 25, 13.7/8.5–38.3 ng/ml, p = 0.003). 
Only two control participants were obese, hence no compari-
son has been performed in obese and non-obese controls. 
Table 1  Patient characteristics of our study population
AHI apnea–hypopnea index, BMI body mass index, ESS Epworth 
Sleepiness Scale, RDI respiratory disturbance index, ODI oxygen 
desaturation index, TST total sleep time, TST90% total sleep time 
with saturation under 90%, AI arousal index, SPT sleep period time
Control N = 42 OSA N = 51 p value
Age (years) 45 ± 16 55 ± 12  < 0.01
Gender (male%) 14 68  < 0.01
BMI (kg/m2) 24.33 ± 4.66 31.18 ± 6.20  < 0.01
Hypertension (%) 30 72 0.01
Diabetes (%) 14 21 0.23
Asthma (%) 9 3 0.55
Aspirin use (%) 4.7 17.6 0.11
Clopidogrel use (%) 2.38 3.9 1
Statin use (%) 2 29  < 0.01
Ever-smokers (%) 9 19 0.28
ESS (points) 5.94 ± 3.29 6.76 ± 3.70 0.29
AHI (events/h) 2.1 ± 1.5 31 ± 26.7  < 0.01
RDI (events/h) 11.3 ± 6.4 41.1 ± 26.2  < 0.01
ODI (events/h) 1.21 ± 1.15 28.75 ± 26.92  < 0.01
MinSat (%) 90.72 ± 3.22 79.34 ± 10.08  < 0.01
TST (min) 379.21 ± 64.76 394.6 ± 82.66 0.38
TST90% (min) 0.28 ± 1.37 14.68 ± 21.26  < 0.01
AI (events/h) 45.73 ± 17.27 45.02 ± 24.75 0.89
SPT 416.08 ± 52.74 432.48 ± 70.75 0.27
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Fig. 1  PSGL-1 levels in our 
population. There was no differ-
ence between the OSA severity 
groups. There was no difference 
between PSGL-1 levels in the 
morning and in the evening
Table 2  PSGL-1 and P-selectin levels in the different severity groups. PSGL-1 shows no significant difference, however P-selectin is signifi-
cantly higher in the severe OSA group compared to controls and mild patients (post-hoc Dunn-test)
KW-test Kruskal–Wallis test
*Statistical significance
Controls OSA (mild) OSA (moderate) OSA (severe) p value (KW-test)
PSGL-1 (morning) U/ml 494.0 /47.0—802.1/ 439.7 /254.2—1265.2/ 347.1 /254.7—663.6/ 522.0 /283.0—1130.8/ 0.43
PSGL-1 (evening) U/ml 480.2 /41.3—1027.7/ 470.4 /50.2—808.6/ 407.5 /163.8—828.5/ 556.4 /55.8—1054.7/ 0.78
P-selectin (morning) ng/ml 16.9 /6.8–40.8/ 14.1 /8.5—35.3/ 17.1 /9.3–48.9/ 25.6 /8.4—56.8/ 0.01*
Fig. 2  P-selectin levels in our 
study group. P-selectin level 
was significantly higher in the 
severe group compared to con-
trols and mild OSA patients
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However, there was no difference in P-selectin between non-
obese OSA and non-obese controls (p = 0.29).
Correlation Between Biomarkers and Clinical 
Parameters
We found no correlation between plasma PSGL-1 levels 
and any other demographic or clinical parameters, includ-
ing indices of OSA severity (all p > 0.05).
P-selectin levels showed a positive correlation with AHI 
(ρ = 0.24, p = 0.02), ODI (ρ = 0.29, p = 0.005), RDI (ρ = 0.29, 
p = 0.005) and BMI (ρ = 0.37, p < 0.001), systolic and dias-
tolic blood pressure in the morning (ρ = 0.30, p = 0.005 and 
ρ = 0.34, p = 0.001 respectively) and fasting glucose level 
(ρ = 0.38, p = 0.001). There was no correlation between 
plasma P-selectin concentrations and any other investigated 
variable.
There was no correlation between smoking (either status 
or pack years) and circulating P-selectin or PSGL-1 levels.
Correlation Between P‑Selectin and PSGL‑1 Levels
There was no correlation between P-selectin and PSGL-1 
levels either measured in the morning or evening either when 
all subjects were investigated together, or when patients 
with OSA or control volunteers were analyzed separately. 
Analyzing the subgroups, a trend for a moderate correla-
tion between P-selectin and morning PSGL-1 were found in 
severe OSA patients (ρ = − 0.53, p = 0.07).
Discussion
In this study, we investigated the circulating levels of 
PSGL-1 in OSA together its receptor, P-selectin. We found 
no difference in PSGL-1 between patients with OSA and 
control participants, nor was there any overnight change 
detected. In contrast, there was a significant increase in 
P-selectin levels in severe OSA patients. However, these 
results should be interpreted carefully as plasma P-selectin 
levels were related to obesity apart from OSA severity. Our 
results suggest that there is no further increase in the expres-
sion of PSGL-1 in OSA and enhanced P-selectin in severe 
disease acts through an unaltered quantity of PSGL-1.
Systemic inflammation plays a role in the development of 
cardiovascular comorbidities in OSA. Although CPAP is an 
effective treatment in sleep apnea, it does not acute reduce 
cardiovascular events in cardiovascular disease [26]. A 
potential reason could be the fact that CPAP does not change 
the levels of inflammatory mediators [27]. This emphasizes 
the need of understanding the elements of systemic inflam-
mation characterizing OSA to identify potential targets for 
drug development. The current study suggests that PSGL-1 
is not altered in OSA, and future studies should investigate 
different inflammatory pathways.
We measured soluble PSGL-1 which may not neces-
sarily reflect membrane bound PSGL-1 concentrations. It 
is known that soluble PSGL-1 increases after granulocyte 
colony-stimulating factor, granulocyte–macrophage col-
ony-stimulating factor, lipopolysaccharide challenge and 
metalloproteases may cleave membrane bound PSGL-1 
as well [16]. The levels of circulating metalloproteases are 
higher in OSA [28]. The unchanged concentration of solu-
ble PSGL-1 in OSA may be due to balance between events 
leading to increased cleavage and decreased production of 
this molecule.
Confirming some previous results [6, 7, 10], we did not 
find a significant difference in plasma P-selectin levels 
between OSA and controls. On the contrary, in line with 
some previous findings [9, 11, 29] severe OSA was asso-
ciated with higher plasma P-selectin concentrations which 
were directly related to markers of disease severity (i.e. AHI, 
ODI and RDI). This is not entirely surprising as mild OSA 
is associated with the activation of some anti-inflammatory 
systems [30], suggesting that mild and more severe patients 
should be investigated separately when analyzing inflam-
matory mechanisms in OSA. Nevertheless, the relationship 
between P-selectin levels and disease severity on one hand 
suggests that enhanced intermittent hypoxia is responsible 
for increased P-selectin expression. However, on the other 
hand, P-selectin increase may be due to comorbid obesity, as 
we found a correlation between P-selectin levels and BMI, 
and P-selectin levels were higher in obese patients with 
OSA. Furthermore, there was no difference in P-selectin 
when non-obese OSA was compared to non-obese controls. 
OSA is frequently associated with obesity [13] which may 
itself induce systemic inflammation [14]. Previous studies 
showed that despite improvement in AHI, neither CPAP [8], 
nor MAD [12] altered circulating P-selectin levels. This sug-
gests that possibly obesity is a more potent factor maintain-
ing high P-selectin concentrations than intermittent hypoxia. 
To test this, trials combining CPAP with weight loss pro-
grams are required with an aim to investigate P-selectin 
in OSA. A previous study reporting high P-selectin levels 
in OSA found a significant association with BMI, but not 
disease severity [8]. In addition, no difference in platelet 
P-selectin expression was observed when patients with OSA 
were compared to weight-matched controls [6]. There was 
also a tendency for higher plasma P-selectin levels in OSA 
patients with comorbid hypertension. Interestingly, this dif-
ference was not present in non-OSA subjects. In addition, 
P-selectin levels were related to blood pressure results. This 
emphasizes that P-selectin may play a role in hypertension 
and subsequent atherosclerosis characterizing OSA [31].
Sleep fragmentation may induce systemic inflammation 
[32]. However, neither PSGL-1, nor P-selectin levels were 
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influenced by sleep quality indices. This is in line with a 
previous study reporting no differences in P-selectin lev-
els between sleepy and non-sleepy patients with OSA [10]. 
There was no correlation between these molecules and 
Epworth sleepiness score, nor PSGL-1 levels changed after 
sleep. Our results suggest that sleep does not influence the 
levels of PSGL-1 itself.
A potential limitation of the study that the controls and 
patients with OSA were not matched. Patients with OSA 
were older, had higher BMI, had higher prevalence of males, 
hypertension and statin use. This is not surprising as these 
factors are associated with OSA [13]. Most notably, there 
was a significant association between plasma P-selectin lev-
els and hypertension as well as BMI. Therefore, increased 
levels observed in severe OSA must be interpreted carefully. 
Of note, neither P-selectin, nor PSGL-1 concentrations were 
related to age, gender or medication usage, still because the 
current study was not powered to investigate these relation-
ships, future studies should aim for matching OSA and con-
trol groups.
In summary, neither P-selectin nor PSGL-1 levels were 
altered in OSA. However, unlike PSGL-1, P-selectin con-
centrations were increased in severe OSA suggesting that 
either intermittent hypoxia or more probably comorbid obe-
sity lead to endothelial and/or platelet activation expressing 
P-selectin. However, unchanged PSGL-1 does not rule out 
the increased activation of P-selectin on the endothelium 
in severe OSA and consequently, the accelerated extravasa-
tion of leukocytes as functional changes in PSGL-1 might 
facilitate ligand-receptor binding.
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